Skip to main content
. Author manuscript; available in PMC: 2019 May 25.
Published in final edited form as: Pharm Nanotechnol. 2018;6(4):232–244. doi: 10.2174/2211738506666180918122337

Fig. (4).

Fig. (4).

Antitumor efficacy using MPs to deliver TLR-3 agonists. TC-1 tumor cells were subcutaneously injected into C57BL/6 mice and treated. Three IP injections of PBS, soluble E7 peptide, chitosan particles (CH-NP) (empty), or chitosan encapsulated E7/Poly I:C particles (CH (E7+polyI:C)-NP) were administered once a week. a) Tumor volume and b) survival were measured over time. c) Tumors were harvested from each treatment group and imaged [94].